Juan Andres - Feb 9, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 9, 2022
Transactions value $
-$402,109
Form type
4
Date filed
2/11/2022, 03:53 PM
Previous filing
Feb 4, 2022
Next filing
Feb 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $28.4K +2K $14.22* 2K Feb 9, 2022 Direct F1
transaction MRNA Common Stock Sale -$309K -2K -100% $154.26 0 Feb 9, 2022 Direct F1
transaction MRNA Common Stock Options Exercise $0 +1.74K $0.00 1.74K Feb 9, 2022 Direct F2
transaction MRNA Common Stock Sale -$122K -768 -44.14% $158.89 972 Feb 10, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2K -7.51% $0.00 24.6K Feb 9, 2022 Common Stock 2K $14.22 Direct F1, F4
transaction MRNA Restricted Stock Units Options Exercise $0 -1.74K -24.99% $0.00 5.22K Feb 9, 2022 Common Stock 1.74K $0.00 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
F5 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer